# Servier Presents Long-Term INDIGO Analyses Demonstrating Sustained Clinical Benefit of VORANIGO® (vorasidenib) in IDH-Mutant Glioma Across Subgroups at SNO 2026

- Source: PR Newswire M&A
- Published: 2026-11-17T21:45:00+00:00
- Category: Business
- Original: https://www.prnewswire.com/news-releases/servier-presents-long-term-indigo-analyses-demonstrating-sustained-clinical-benefit-of-voranigo-vorasidenib-in-idh-mutant-glioma-across-subgroups-at-sno-2026-302942884.html
- Canonical: https://groundlevelnews.com/story/servier-presents-long-term-indigo-analyses-demonstrating-sustained-cli-e77cab/

Extended Phase 3 INDIGO follow-up results, including data from patients who crossed over to VORANIGO® (vorasidenib) from placebo, were presented as an oral presentation on November 14 Exploratory INDIGO analysis providing insight into VORANIGO's impact on seizure control and quality of...

_Ground Level News shows a short summary only; the full article and all rights belong to PR Newswire M&A._
